Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

The <keyword id="6364555" type="General" weightage="50" keywordseo="indian-council-of-medical-research" source="Orion">Indian Council of Medical Research</keyword> (<keyword id="6364396" type="General" weightage="100" keywordseo="icmr" source="Orion">ICMR</keyword>) has sought proposals in <keyword id="619017" type="General" weightage="80" keywordseo="stillbirths" source="Orion">stillbirths</keyword> under the <keyword id="15545302" type="General" weightage="50" keywordseo="icmr-task-force-programme" source="Orion">ICMR Task Force Programme</keyword> for research funding. The concept proposals with specific objectives and scientific questions should be submitted online by December 30, 2022, by 5 pm, it said. "<keyword id="113952" type="General" weightage="50" keywordseo="stillbirth" source="Orion">Stillbirth</keyword>s are a hidden tragedy that impacts millions of women and families across the globe daily. The stillbirth rate may be one of the indicators of the quality of a country's medical system. Stillbirth has multifactorial etiologies. Early identification of risk factors for stillbirth and appropriate antenatal management may reduce preventable stillbirths and improve the pregnancy outcomes," the ICMR said in a release. The ICMR Call for Proposals in Stillbirths, under the ICMR Task Force Programme, further states that the initiative is in line with the government's aim of bringing the number of stillbirths in the country down to single digits by 2030. "The INAP by the Government of India now plans to bring down stillbirths to single digits by 2030. There is a need for research into the causes of stillbirth and effective prevention and treatment of these causes identifying research challenges. The ICMR expert group on Still Births has identified three key thematic areas to prioritise and articulate research challenges," the ICMR said. "The concept proposal can be submitted for financial support through online mode only by scientists/ professionals, who have regular employment in medical institutes/research institutes/ universities/colleges/recognised research and development laboratories/government and semi-government organisations and NGOs (documentary evidence of their recognition including DSIR certificate should be enclosed with the proposal)," the ICMR release further stated. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/science/health/news/cervical-cancer-4th-most-common-among-women-policymakers-should-urgently-move-to-eliminate-who/articleshow/95580233.cms">Cervical cancer 4th most common among women, policymakers should urgently move to eliminate: WHO</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/science/health/news/covid-19-infection-may-reactivate-several-latent-viruses-in-body-study/articleshow/95581176.cms">Covid-19 can reactivate latent viruses lurking in the body's cells</a>

Stillbirths are a hidden tragedy says ICMR as it seeks research funding

The <keyword id="26362" type="ORGANIZATION" weightage="20" keywordseo="Government">government</keyword> on Monday revised the clinical guidance for COVID-19 treatment, dropping the off-label use of <keyword id="8956772" type="UNKNOWN" weightage="20" keywordseo="convalescent-plasma">convalescent plasma</keyword> as it was found not beneficial in reducing the progression to severe disease or death. The development came following a meeting of the ICMR-National Task Force for COVID-19 last week wherein all members were in favour of removing the use of convalescent plasma from the <keyword id="6379119" type="UNKNOWN" weightage="20" keywordseo="guidelines">guidelines</keyword> citing its ineffectiveness and inappropriate use in several cases. An Indian Council of Medical Research (<keyword id="6364396" type="COMPANY" weightage="20" keywordseo="ICMR">ICMR</keyword>) official said the task force "revised" the Clinical Guidance for Management of Adult COVID-19 Patients and "dropped convalescent plasma (off label)". The previous guidelines recommended off-label use of plasma therapy at the stage of early moderate disease, that is, within seven days of the onset of symptoms and if there is availability of a high titre donor plasma. The decision to remove it from the guidelines comes in the backdrop of some clinicians and scientists writing to Principal Scientific Advisor K VijayRaghavan cautioning against the "irrational and non-scientific use" of convalescent plasma for COVID-19 in the country. In the letter, which was also marked to ICMR chief Balram Bhargava and <keyword id="40458" type="COMPANY" weightage="20" keywordseo="AIIMS">AIIMS</keyword> Director Randeep Guleria, public health professionals alleged that the current guidelines on plasma therapy are not based on existing evidence and pointed out some very early evidence that indicates a possible association between emergence of variants with "lower susceptibility to neutralising antibodies in immunosuppressed" people given plasma therapy. This raises the possibility of more virulent strains developing due to irrational use of plasma therapy which can fuel the pandemic, according to the letter signed by vaccinologist Gagandeep Kang, surgeon Pramesh C S and others. "We are writing to you as concerned clinicians, public health professionals and scientists from <keyword id="3658" type="LOCATION" weightage="20" keywordseo="India">India</keyword> about the irrational and non- scientific use of convalescent plasma for COVID-19 in the country. "This has stemmed from guidelines issued by government agencies, and we request your urgent intervention to address the issue which can prevent harassment of COVID-19 patients, their families, their clinicians and COVID-19 survivors," said the letter. "The current research evidence unanimously indicates that there is no benefit offered by convalescent plasma for treatment of COVID-19. However, it continues to be prescribed rampantly in hospitals across India," the letter said. SEE ALSO: <a href="https://www.businessinsider.in/tech/news/google-said-to-rival-apples-privacy-push-with-android-12-while-taking-care-of-its-advertising-business/articleshow/82729724.cms">Google said to rival Apple’s privacy push with Android 12 while taking care of its advertising business</a> <a href="https://www.businessinsider.in/tech/news/facebooks-mark-zuckerberg-has-six-months-to-answer-these-five-questions/articleshow/82729482.cms">Facebook’s Mark Zuckerberg has six months to answer these five questions</a> <a href="https://www.businessinsider.in/cryptocurrency/news/indian-cryptocurrency-exchange-wazirx-has-listed-shiba-inu-tokens-for-trading-in-indian-rupees/articleshow/82731429.cms">WazirX has listed Shiba Inu — here's everything you need to know about the said Dogecoin killer</a>

Indian government drops plasma therapy from guidelines for COVID-19 management

<ul class="summary-list"><li>President Donald <keyword id="6354862" type="UNKNOWN" weightage="60" keywordseo="trump">Trump</keyword> on Tuesday held his first coronavirus-focused briefing in months.</li><li>He was alone at the podium, though he told reporters that Dr. Deborah Birx was right outside the door. Dr. Anthony Fauci was not present.</li><li>Fauci told <a href="https://www.cbsnews.com/news/trump-press-conference-today-return-coronavirus-task-force-briefings-2020-07-21/">CBS News</a> that he wasn't told anything about attending the press conference.</li></ul>President Donald Trump on Tuesday held his first <keyword id="1754604" type="PERSON" weightage="60" keywordseo="coronavirus">coronavirus</keyword>-focused briefing in months, and he did so without members of the White House coronavirus <keyword id="52882" type="ORGANIZATION" weightage="60" keywordseo="Task-Force">task force</keyword>.Trump was accompanied only by the White House press secretary, Kayleigh McEnany, and he told reporters that Dr. Deborah Birx — the task force's coordinator — was right outside the door. He did not answer why he was not accompanied by Dr. Anthony Fauci, the leading infectious-disease expert in the US.During his relatively short Tuesday briefing, Trump talked mostly about testing, ventilators, and mask use, though he did answer a reporter's question about the sex-trafficking suspect and Jeffrey Epstein associate <a href="https://www.businessinsider.com/trump-ghislaine-maxwell-epstein-i-wish-her-well-video-2020-7">Ghislaine Maxwell, saying he wished her well</a>.Public-health officials were not present. Fauci, the director of the National Institute of Allergy and Infectious Diseases, told <a href="https://www.cbsnews.com/news/trump-press-conference-today-return-coronavirus-task-force-briefings-2020-07-21/">CBS News</a> he wasn't told anything about attending the press conference.Never miss out on healthcare <keyword id="6355005" type="UNKNOWN" weightage="100" keywordseo="news">news</keyword>. <a href="http://newsletter.businessinsider.com/join/4np/dispensed-daily">Subscribe to Dispensed</a>, Business Insider's daily newsletter on pharma, biotech, and healthcare. <a href="http://newsletter.businessinsider.com/join/4np/dispensed-daily" target="_blank" rel="noopener"></a>Trump's relationship with Fauci is thought to be more distant, and multiple White House officials tried recently to undercut Fauci, an effort on which the White House later backed down.The president recently called Fauci <a href="https://www.businessinsider.com/trump-fauci-alarmist-coronavirus-outbreaks-worsens-us-2020-7">"a little bit of an alarmist" over his stark warnings about the coronavirus pandemic.</a> Cases and deaths in the US have continued to surge, and the country has repeatedly hit daily records of new cases.Read more: <a href="https://www.businessinsider.com/top-coronavirus-treatments-in-development-timeline-2020-7">Here are the most promising coronavirus treatments that could be ready by the fall.</a>Fauci has advised that states reopen slowly and reconsider imposing restrictions as cases continue to rise. He's also in support of wearing masks. Trump did advise people to wear masks during Tuesday's briefing but has stopped short of calling for mask mandates and has mostly refused to wear a mask himself.

Trump gave his first coronavirus briefing since April, and none of the other members of the coronavirus task force were in the room

A total of 7.9 per cent of all cancer cases between 2012-19 were found in children below 14 years, a report prepared by the <keyword id="6364555" type="General" weightage="20" keywordseo="Indian-Council-of-Medical-Research" source="Orion">Indian Council of Medical Research</keyword> said. "Clinicopathological Profile of Cancers in India: A Report of the Hospital-Based Cancer Registries, 2021", consolidates data collected during the period across 96 hospital-based cancer registries under the <keyword id="421743" type="General" weightage="20" keywordseo="national-cancer-registry-programme" source="Orion">National Cancer Registry Programme</keyword> (NCRP). The data pertains to all diagnosed and treated cases of confirmed malignancies reported to these centres across the country The country registered 13,32,207 cases of cancer during 2012-19. Of these, 6,10,084 were included for analysis, based on the completeness and quality of data. Childhood cancers rank ninth as a leading cause of childhood diseases at the global level, accounting for 11.5 million of the <keyword id="8118522" type="General" weightage="20" keywordseo="Disability-Adjusted-Life-Years" source="Orion">Disability Adjusted Life Years</keyword> (DALYs). In India, according to a recent NCRP report, the proportion of childhood cancers (0-19 years), relative to cancers in all age groups, was found to range from 1 per cent to 4.9 per cent. Delhi reported the highest age-adjusted incidence rate (AAR) of 203.1 per million in boys and 125.4 per million in girls. Leukaemia accounted for nearly half of all the childhood cancers in both genders in the 0-14 years age group (46.4 per cent in boys and 44.3 per cent in girls). The other common childhood cancer in boys was lymphoma (16.4 per cent), while in girls, it was malignant bone tumour (8.9 per cent). Childhood cancers are presented for two age groups: 0-14 years and 0-19 years to enable national and international comparison, and classified according to the International Classification of Childhood Cancer. Apart from childhood cancer, the <keyword id="6958288" type="General" weightage="20" keywordseo="ICMR-report" source="Orion">ICMR report</keyword> says that cancers in sites associated with tobacco use comprised 48.7 per cent of cancers among males and 16.5 per cent among females. The relative proportion of site-specific cancers was higher in males than females except for thyroid cancer (2.5 per cent in females versus 1 per cent in males) and gall bladder cancer (3.7 per cent in females versus 2.2 per cent in males). Among all the cancers, the highest proportion of distant metastasis at presentation was seen in patients with lung cancer (49.2 per cent males and 55.5 per cent females), followed by gall bladder cancer (40.9 per cent males and 45.7 per cent females) and prostate cancer (42.9 per cent). The <keyword id="6364396" type="General" weightage="20" keywordseo="ICMR" source="Orion">ICMR</keyword> reports suggested that chemotherapy was still the most typical treatment modality for many cancers, regardless of the clinical extent of disease at presentation, including cancers of the liver, gall bladder, stomach, lung, and childhood cancers. SEE ALSO <a href="https://www.businessinsider.in/india/news/highlights-of-prime-minister-narendra-modis-speech-at-the-unga-today/articleshow/86510462.cms">Indian Prime Minister Narendra Modi makes his points on China, Afghanistan and Pakistan at the United Nations General Assembly</a> <a href="https://www.businessinsider.in/thelife/personalities/freshworks-ceo-girish-mathrubootham-shares-someone-said-i-will-be-nothing-but-a-rickshaw-puller/articleshow/86507840.cms">WATCH: "Someone said I am good enough to be a rickshaw puller," shares Freshworks CEO Girish Mathrubootham in a candid chat</a>

Out of all cancer cases, 7.9% were found in children below 14 years, reveals ICMR report

Experts of the <keyword id="6364396" type="General" weightage="20" keywordseo="ICMR" source="Orion">ICMR</keyword>'s National Task Force on COVID-19 for the fourth time have unanimously rejected the inclusion of <keyword id="9385138" type="General" weightage="20" keywordseo="anti-viral-drug" source="Orion">anti-viral drug</keyword> <keyword id="10880838" type="General" weightage="20" keywordseo="Molnupiravir" source="Orion">Molnupiravir</keyword> in the coronavirus treatment guidelines saying its "known and unknown harms far outweigh its claimed benefit". Responding to a question over Molnupiravir's inclusion in the treatment guidelines amid doctors prescribing it, ICMR Director General Dr Balram Bhargava said experts have had extensive debate and discussions and reviewed the data available from three trials on the drug on Monday. "We had extensive deliberation and the final conclusion was that Molnupiravir has certain risks that warrant caution in its use. Experts present in the meeting opined that there is a rampant and irrational use of Molnupiravir. Efforts should be made to restrict its use as known and unknown harms far outweigh its claimed benefit," he said on Wednesday. "The currently available synthesised evidence was reviewed and the members unanimously agreed that it does not merit the inclusion of Molnupuravir in the national treatment guidelines for COVID-19," Bhargava said. The emerging evidence will constantly be reviewed, he added. "And lastly it was further highlighted the current clinical window of application appears extremely narrow for Molnupiravir with relevance only to the following --elderly, unvaccinated, with other comorbidities. "There was no evidence of benefit in diabetes and those who were previously infected with COVID-19 or were vaccinated," he said. India's drug regulator on December 28 had approved the anti-Covid pill for restricted use in emergency situations. Molnupiravir is an antiviral that inhibits SARS-CoV-2 replication by viral mutagenesis, the health ministry earlier had said in a statement. The UK MHRA on December 4 granted approval for Molnupiravir under special condition for treatment of mild to moderate COVID-19 in adults with a positive SARS-COV-2 diagnostic test and who have at least one risk factor for developing severe illness. The USFDA on December 23 granted Emergency Use Authorisation (EUA) for Molnupiravir for treatment of mild-to-moderate COVID-19 in adults with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalisation or death, and for whom alternative <keyword id="8918466" type="General" weightage="20" keywordseo="COVID-19-treatment" source="Orion">COVID-19 treatment</keyword> options authorised by the FDA are not accessible or clinically appropriate. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/science/health/news/study-shows-booster-dose-of-covaxin-has-neutralising-effect-on-omicron-delta-variants-says-bharat-biotech/articleshow/88867266.cms">Study shows booster dose of Covaxin has neutralising effect on Omicron, Delta variants, says Bharat Biotech</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/tech/enterprise/news/tcs-vs-infosys-vs-wipro-how-indias-three-it-giants-stack-up-against-each-other/slidelist/88860676.cms">TCS vs Infosys vs Wipro Q3 results – here’s how India’s three IT giants stack up against each other</a>

ICMR experts reject inclusion of Molnupiravir in COVID-19 treatment guidelines for fourth time citing safety concerns

<ul class="summary-list"><li>The <keyword id="6379474" type="ORGANIZATION" weightage="60" keywordseo="cdc">CDC</keyword> no longer recommends tests for people without <keyword id="1754604" type="PERSON" weightage="60" keywordseo="coronavirus">coronavirus</keyword> symptoms, even if they've potentially been exposed to the virus.</li><li>The agency updated its guidelines on Monday after the White House <keyword id="8932342" type="UNKNOWN" weightage="60" keywordseo="coronavirus-task-force">Coronavirus task force</keyword> approved the change.</li><li>But one of the task force's key members, Dr. Anthony Fauci, was in surgery while the group met on Thursday.</li><li>"I was under general anesthesia in the operating room and was not part of any discussion or deliberation regarding the new testing recommendations," Fauci <a href="https://www.cnn.com/2020/08/26/politics/fauci-coronavirus-cdc-testing/index.html">told CNN</a>.</li></ul>The Centers for Disease Control and Prevention instituted a major change to the nation's <keyword id="8693569" type="UNKNOWN" weightage="60" keywordseo="Coronavirus-testing">coronavirus testing</keyword> guidelines on Monday.The agency previously recommended tests for anyone with recent or suspected exposure to the virus. Now it suggests that people who aren't showing symptoms don't require a test — even if they've had contact with an infected person.Two federal health officials <a href="https://www.nytimes.com/2020/08/26/world/covid-19-coronavirus.html">told the New York Times</a> on Wednesday that higher-ups in President Donald Trump's administration had pressured the CDC to alter its testing guidelines. Later that day, CNN reported that Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, had been <a href="https://www.cnn.com/2020/08/26/politics/fauci-coronavirus-cdc-testing/index.html">absent for a conversation</a> about whether the testing criteria should change.Fauci was in surgery on August 20, when the White House Coronavirus Task Force held a meeting to discuss the change in strategy."I was under general anesthesia in the operating room and was not part of any discussion or deliberation regarding the new testing recommendations," Fauci told CNN Chief Medical Correspondent Dr. Sanjay Gupta. "I am concerned about the interpretation of these recommendations and worried it will give people the incorrect assumption that asymptomatic spread is not of great concern. In fact it is."US Health and Human Services Assistant Secretary Dr. Brett Giroir <a href="https://www.cnn.com/2020/08/26/politics/cdc-coronavirus-testing-guidance/index.html">told CNN</a> on Wednesday that the guidelines had "been updated to reflect current evidence and best public health practices."But overwhelming evidence continues to suggest that asymptomatic cases are a key part of coronavirus transmission in the US. The CDC currently estimates that asymptomatic cases <a href="https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html">represent around 40% of the nation's COVID-19 infections</a>.In <a href="https://www.nejm.org/doi/full/10.1056/NEJMe2009758?query=recirc_curated">a May editorial</a> in the New England Journal of Medicine, researchers at the University of California, San Francisco, called asymptomatic spread the "Achilles heel" of coronavirus mitigation strategies. Without testing asymptomatic patients, they said, the US might struggle to contain its outbreak.<h2>Conflict between the White House and CDC has alarmed health experts</h2>In recent months, many public-health experts have expressed concern about the CDC being hamstrung by political pressure.In May, a CDC official <a href="https://apnews.com/7a00d5fba3249e573d2ead4bd323a4d4">told the Associated Press</a> that the White House had ignored the agency's guidelines for reopening public places in favor of a more aggressive reopening strategy. The CDC's daily press briefings were also placed on an abrupt, three-month hiatus after Dr. Nancy Messonnier, director of the agency's National Center for Immunization and Respiratory Diseases, warned in March that the virus would inevitably spread throughout the US."They need to stop muzzling scientists," Dr. Leana Wen, a public-health professor at George Washington University who previously served as Baltimore's Health Commissioner, said of the White House's pandemic response.Now experts fear that scientists are being ignored yet again.<div type="image" title="coronavirus testing montana" height="1668" width="2500" msid="77774596" hostid="261"></div>"The CDC's changing testing recommendations discovered today appear to represent yet another disturbing example of mixed and inconsistent health messaging from the administration throughout the pandemic," Dr. Howard Koh, a professor at the Harvard TH Chan School of Public Health, said in a statement.He added: "No new <keyword id="41551" type="ENTERTAINMENT" weightage="100" keywordseo="science">science</keyword>, data, or research have been offered to justify such a change. Moreover, no basic explanations have yet been offered to health professionals or the general public."<h2>Failure to test asymptomatic cases already allowed the virus to spread</h2>The US currently <a href="https://coronavirus.jhu.edu/testing/international-comparison">ranks fourth in the world</a> in terms of coronavirus testing per capita with around 205 average daily tests per 100,000 people. In total, more than 73 million people in the US have been tested so far.But the nation's <a href="https://www.businessinsider.com/us-coronavirus-testing-decline-shortages-delays-2020-8">testing capacity declined in August</a> as diagnostic companies struggled to return results quickly and California reported a major backlog of testing data. This presented a challenge for contact tracers, who were already struggling to identify new cases before they went on to infect others.Ideally, public-health experts say, the US would get to a point where <a href="https://www.businessinsider.com/us-coronavirus-strategy-under-joe-biden-kamala-harris-2020-8">every person could receive a coronavirus test</a>. But President Donald Trump has referred to testing as "a double-edged sword" that reflects poorly on the US."I personally think testing is overrated, even though I created the greatest testing machine in history," Trump <a href="https://www.wsj.com/articles/trump-talks-juneteenth-john-bolton-economy-in-wsj-interview-11592493771?mod=breakingnews">told the Wall Street Journal</a> in June. He added that <a href="https://www.businessinsider.com/trump-coronavirus-testing-is-overrated-makes-us-look-bad-2020-6">a rise in testing leads to a rise in cases</a>, which "makes us look bad."But experts say the nation's 5.8 million cases reflect the scale of its outbreak. In fact, researchers estimate that the official case count <a href="https://www.businessinsider.com/real-us-coronavirus-cases-compared-to-official-count-2020-7">would likely be 10 times larger</a> if the US had tested more at the start of the outbreak when a shortage of accurate tests meant only patients with severe <a href="https://www.businessinsider.com/coronavirus-covid19-day-by-day-symptoms-patients-2020-2">symptoms</a> were eligible."We have already seen how limiting testing to only symptomatic individuals does not work to reduce contagion," Zenei Cortez, president of the National Nurses United, said in a statement on Wednesday. "It has cost many lives."

You Searched For "icmr task force programme" and got 6 results

Stillbirths are a hidden tragedy says ICMR as it seeks research funding

ANI

Indian government drops plasma therapy from guidelines for COVID-19 management

PTI

Trump gave his first coronavirus briefing since April, and none of the other members of the coronavirus task force were in the room

Sarah Al-Arshani

Out of all cancer cases, 7.9% were found in children below 14 years, reveals ICMR report

IANS

ICMR experts reject inclusion of Molnupiravir in COVID-19 treatment guidelines for fourth time citing safety concerns

PTI

The White House discussed changing CDC guidelines about testing asymptomatic people while Fauci was under anesthesia

Aria Bendix

Popular Keywords

Buying Guides